Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations

Hastings Center Report

Volumn 47, Issue 2, 2017, Pages 16-20

  Hey, Spencer Phillips ^a   Kesselheim, Aaron S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG APPROVAL; DRUG INDUSTRY; ETHICS; HUMAN; LEGISLATION AND JURISPRUDENCE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; POLICY; UNITED STATES;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HUMANS; POLICY; UNITED STATES;

EID: 85015712021     PISSN: 00930334     EISSN: 1552146X     Source Type: Journal    
DOI: 10.1002/hast.685     Document Type: Article

References (40)

1. R. Laxminarayan et al., “Antibiotic Resistance—the Need for Global Solutions,” Lancet Infectious Diseases 13, no. 12 (2013): 1057–98;
2. O. P. Keown et al., “Antimicrobial Resistance: Addressing the Global Threat through Greater Awareness and Transformative Action,” Health Affairs 33, no. 9 (2014): 1620–26;
3. C. Nathan and O. Cars, “Antibiotic Resistance—Problems, Progress, and Prospects,” New England Journal of Medicine 371 (2014): 1761–63.
4. H. W. Boucher et al., “Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America,” Clinical Infectious Diseases 48 (2009): 1–12.
5. S. B. Levy and B. Marshall, “Antibacterial Resistance Worldwide: Causes, Challenges and Responses,” Nature Medicine 10 (2004): S122–S129;
6. A. E. Aiello et al., “Antimicrobial Resistance and the Ethics of Drug Development,” American Journal of Public Health 96, no. 11 (2006): 1910–14;
7. L. D. Högberg et al., “The Global Need for Effective Antibiotics: Challenges and Recent Advances,” Trends in Pharmacological Sciences 31, no. 11 (2010): 509–15.
8. S. Nambiar et al., “Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations,” Clinical Pharmacology & Therapeutics 96, no. 2 (2014): 147–49.
9. D. Deak et al., “Progress in the Fight against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010–2015,” Annals of Internal Medicine 165, no. 5 (2016): 363–72.
10. N. Daniels, Just Health Care (New York: Cambridge University Press, 1985).
11. M. Millar, “Can Antibiotic Use Be Both Just and Sustainable … or Only More or Less So?,” Journal of Medical Ethics 37, no. 3 (2010): 153–57.
12. A. Zumla et al., “Advances in the Development of New Tuberculosis Drugs and Treatment Regimens,” Nature Reviews Drug Discovery 12, no. 5 (2013): 388–404.
13. D. Yee et al., “Incidence of Serious Side Effects from First-line Antituberculosis Drugs among Patients Treated for Active Tuberculosis,” American Journal of Respiratory and Critical Care Medicine 167, no. 11 (2003): 1472–77;
14. N. Awofeso, “Anti-tuberculosis Medication Side-Effects Constitute Major Factor for Poor Adherence to Tuberculosis Treatment,” Bulletin of the World Health Organization 86, no. 3 (2008): B-D.
15. E. Sumartojo, “When Tuberculosis Treatment Fails: A Social Behavioral Account of Patient Adherence,” American Review of Respiratory Disease 147, no. 5 (1993): 1311–20;
16. S. Thiam, “Effectiveness of a Strategy to Improve Adherence to Tuberculosis Treatment in a Resource-Poor Setting: A Cluster Randomized Controlled Trial,” Journal of the American Medical Association 297, no. 4 (2007): 380–86.
17. R. Menzies et al., “Factors Associated with Compliance in Treatment of Tuberculosis,” Tubercle and Lung Disease 74, no. 1 (1993): 32–37.
18. M. T. G. Holden et al., “A Genomic Portrait of the Emergence, Evolution, and Global Spread of a Methicillin-Resistant Staphylococcus Aureus Pandemic,” Genome Research 23, no. 4 (2013): 653–64.
19. J. Avorn and D. H. Solomon, “Cultural and Economic Factors That (Mis)Shape Antibiotic Use: The Nonpharmacologic Basis of Therapeutics,” Annals of Internal Medicine 133, no. 2 (2000): 128–35.
20. Aiello et al., “Antimicrobial Resistance”;
21. Millar, “Can Antibiotic Use?”
22. B. M. Marshall and S. B. Levy, “Food Animals and Antimicrobials: Impacts on Human Health,” Clinical Microbiology Reviews 24, no. 4 (2011): 718–33.
23. L. Brooks et al., “Towards a Better Understanding of Patients’ Perspectives of Antibiotic Resistance and MRSA: A Qualitative Study,” Family Practice 25, no. 5 (2008): 341–48.
24. R. Deschepper and R. Van der Stichele, “Differences in Use of Antibiotics in Europe: The Role of Cultural Aspects,” Pharmaceutisch Weekblad 136 (2001): 794–97;
25. S. Harbarth et al., “Outpatient Antibiotic Use and Prevalence of Antibiotic-Resistant Pneumococci in France and Germany: Sociocultural Perspective,” Emerging Infectious Diseases 8, no. 12 (2002): 1460–67.
26. S. H. Podolsky, The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics (Baltimore, MD: Johns Hopkins University Press, 2014).
27. D. B. Ross, “The FDA and the Case of Ketek,” New England Journal of Medicine 356 (2007): 1601–04.
28. P. Ball, “Quinolone-Induced QT Interval Prolongation: A Not-So-Unexpected Class Effect,” Journal of Antimicrobial Chemotherapy 45, no. 5 (2000): 557–59;
29. K. Outterson et al., “Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980–2009,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 688–96.
30. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Washington, D.C.: Government Printing Office, 1979);
31. C. Weijer and P. B. Miller, “When Are Research Risks Reasonable in Relation to Anticipated Benefits?,” Nature Medicine 10, no. 6 (2004): 570–73.
32. M. Hay et al., “Clinical Development Success Rates for Investigational Drugs,” Nature Biotechnology 32, no. 1 (2014): 40–51.
33. Outterson et al., “Approval and Withdrawal.”
34. H. Jonas, “Philosophical Reflections on Experimenting with Human Subjects,” Daedalus 98 (1969): 219–47.
35. Millar, “Can Antibiotic Use?”
36. I. Chalmers et al., “How to Increase Value and Reduce Waste When Research Priorities Are Set,” Lancet 383, no. 9912 (2014): 156–65.
37. G. Kolata, “A New, Life-or-Death Approach to Funding Heart Research,” New York Times, October16, 2015.
38. S. P. Hey et al., “Accumulating Evidence and Research Organization (AERO) Model: A New Tool for Representing, Analyzing, and Planning a Translational Research Program,” Trials 14 (2013): 159;
39. B. Carlisle et al., “Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib,” Journal of the National Cancer Institute 108, no. 1 (2016): djv292;
40. B. Barsanti-Innes et al., “The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing,” Oncologist (2016), epub early, doi: theoncologist.2016-0188.